Literature DB >> 21805418

AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Fatih Güzelbulut1, Züleyha Akkan Çetınkaya, Mesut Sezıklı, Bülent Yaşar, Selvinaz Ozkara, Ayşe Oya Kurdaş Övünç.   

Abstract

BACKGROUND/AIMS: The aim of this study was to evaluate the diagnostic accuracy of aspartate aminotransferase-platelet ratio index, the Forns index and FIB-4 for the assessment of hepatic fibrosis in chronic hepatitis C patients by comparison with liver biopsy.
METHODS: We retrospectively reviewed our computerized data of chronic hepatitis C patients who admitted to the Gastroenterology Clinic between 2004 and 2008. Treatment-naive chronic hepatitis C patients who had undergone liver biopsy and had laboratory test results allowing the calculation of aspartate aminotransferase-platelet ratio index, the Forns index and FIB-4 were included in this study. The degree of fibrosis was scored according to the METAVIR staging system. Significant fibrosis was defined as F2-4 and cirrhosis as F4. Aspartate aminotransferase-platelet ratio index, the Forns index and FIB-4 were calculated based on the original studies. Tests results were compared between groups F0-1 (no or mild fibrosis) versus F2-4 (significant fibrosis) and F03 (no cirrhosis) versus F4 (cirrhosis).
RESULTS: One hundred and fifty patients with chronic hepatitis C were included in this study. The areas under the ROC curves of the Forns index, aspartate aminotransferase-platelet ratio index and FIB-4 to predict significant fibrosis were 0.795, 0.774 and 0.764, respectively. The area under the ROC curves of the Forns index, aspartate aminotransferase-platelet ratio index and FIB-4 to predict cirrhosis were 0.879, 0.839 and 0.874, respectively.
CONCLUSIONS: The Forns index, aspartate aminotransferase-platelet ratio index and FIB-4 were accurate noninvasive blood tests to predict the presence or absence of significant fibrosis and cirrhosis in half of the chronic hepatitis C patients. The Forns index was slightly better than the aspartate aminotransferase-platelet ratio index and FIB-4 in the prediction of significant fibrosis and cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21805418     DOI: 10.4318/tjg.2011.0213

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  10 in total

1.  Prevalence and Prognostic Significance of Liver Fibrosis in Patients With Aneurysmal Subarachnoid Hemorrhage.

Authors:  Tiangui Li; Peng Wang; Xiao Gong; Weelic Chong; Yang Hai; Chao You; Juan Kang; Fang Fang; Yu Zhang
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

Review 2.  Non-invasive diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Leonardo de Lucca Schiavon; Janaína Luz Narciso-Schiavon; Roberto José de Carvalho-Filho
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage.

Authors:  Pamela Valva; Daniela A Ríos; Elena De Matteo; Maria V Preciado
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

4.  Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.

Authors:  Rui Huang; Huiying Rao; Ming Yang; Yinghui Gao; Jian Wang; Qian Jin; Danli Ma; Lai Wei
Journal:  Dig Dis Sci       Date:  2019-10-25       Impact factor: 3.199

5.  SASLT practice guidelines: management of hepatitis C virus infection.

Authors:  Abdullah S Alghamdi; Faisal M Sanai; Mona Ismail; Hamdan Alghamdi; Khalid Alswat; Adel Alqutub; Ibrahim Altraif; Hemant Shah; Faleh Z Alfaleh
Journal:  Saudi J Gastroenterol       Date:  2012-09       Impact factor: 2.485

Review 6.  Hepatic steatosis and fibrosis: Non-invasive assessment.

Authors:  Rustam N Karanjia; Mary M E Crossey; I Jane Cox; Haddy K S Fye; Ramou Njie; Robert D Goldin; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

7.  FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study.

Authors:  Roberto Catanzaro; Alice Aleo; Morena Sciuto; Luca Zanoli; Baskar Balakrishnan; Francesco Marotta
Journal:  Clin Exp Hepatol       Date:  2021-03-25

Review 8.  MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.

Authors:  Nancy de Los Ángeles Segura-Azuara; Carlos Daniel Varela-Chinchilla; Plinio A Trinidad-Calderón
Journal:  Front Med (Lausanne)       Date:  2022-01-13

9.  Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus.

Authors:  Yoshihiko Tachi; Takanori Hirai; Hidenori Toyoda; Toshifumi Tada; Kazuhiko Hayashi; Takashi Honda; Masatoshi Ishigami; Hidemi Goto; Takashi Kumada
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

10.  Relationship between platelet-based models and the prognosis of patients with malignant hepatic tumors.

Authors:  Chen-Liang Hu; Qian-Cheng Du; Zhi-Xin Wang; Ming-Quan Pang; Yan-Yan Wang; Ying-Yu Li; Ying Zhou; Hai-Jiu Wang; Hai-Ning Fan
Journal:  Oncol Lett       Date:  2020-01-17       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.